Cargando…

Pulmonary vasoconstrictor action of KCNQ potassium channel blockers

BACKGROUND: KCNQ channels have been widely studied in the nervous system, heart and inner ear, where they have important physiological functions. Recent reports indicate that KCNQ channels may also be expressed in portal vein where they are suggested to influence spontaneous contractile activity. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Shreena, Balan, Prabhu, Gurney, Alison M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1395307/
https://www.ncbi.nlm.nih.gov/pubmed/16504007
http://dx.doi.org/10.1186/1465-9921-7-31
_version_ 1782126942531616768
author Joshi, Shreena
Balan, Prabhu
Gurney, Alison M
author_facet Joshi, Shreena
Balan, Prabhu
Gurney, Alison M
author_sort Joshi, Shreena
collection PubMed
description BACKGROUND: KCNQ channels have been widely studied in the nervous system, heart and inner ear, where they have important physiological functions. Recent reports indicate that KCNQ channels may also be expressed in portal vein where they are suggested to influence spontaneous contractile activity. The biophysical properties of K(+ )currents mediated by KCNQ channels resemble a current underlying the resting K(+ )conductance and resting potential of pulmonary artery smooth muscle cells. We therefore investigated a possible role of KCNQ channels in regulating the function of pulmonary arteries by determining the ability of the selective KCNQ channel blockers, linopirdine and XE991, to promote pulmonary vasoconstriction. METHODS: The tension developed by rat and mouse intrapulmonary or mesenteric arteries was measured using small vessel myography. Contractile responses to linopirdine and XE991 were measured in intact and endothelium denuded vessels. Experiments were also carried out under conditions that prevent the contractile effects of nerve released noradrenaline or ATP, or block various Ca(2+ )influx pathways, in order to investigate the mechanisms underlying contraction. RESULTS: Linopirdine and XE991 both contracted rat and mouse pulmonary arteries but had little effect on mesenteric arteries. In each case the maximum contraction was almost as large as the response to 50 mM K(+). Linopirdine had an EC(50 )of around 1 μM and XE991 was almost 10-fold more potent. Neither removal of the endothelium nor exposure to phentolamine or α,β-methylene ATP, to block α(1)-adrenoceptors or P2X receptors, respectively, affected the contraction. Contraction was abolished in Ca(2+)-free solution and in the presence of 1 μM nifedipine or 10 μM levcromakalim. CONCLUSION: The KCNQ channel blockers are potent and powerful constrictors of pulmonary arteries. This action may be selective for the pulmonary circulation as mesenteric arteries showed little response. The results imply that the drugs act directly on smooth muscle cells and contraction requires voltage-dependent Ca(2+ )influx. It is concluded that the drugs probably act by blocking KCNQ channels in pulmonary artery myocytes, leading to membrane depolarization and Ca(2+ )influx through L-type Ca(2+ )channels. This implies a functional role for KCNQ channels in regulating the resting membrane potential of pulmonary artery myocytes.
format Text
id pubmed-1395307
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-13953072006-03-09 Pulmonary vasoconstrictor action of KCNQ potassium channel blockers Joshi, Shreena Balan, Prabhu Gurney, Alison M Respir Res Research BACKGROUND: KCNQ channels have been widely studied in the nervous system, heart and inner ear, where they have important physiological functions. Recent reports indicate that KCNQ channels may also be expressed in portal vein where they are suggested to influence spontaneous contractile activity. The biophysical properties of K(+ )currents mediated by KCNQ channels resemble a current underlying the resting K(+ )conductance and resting potential of pulmonary artery smooth muscle cells. We therefore investigated a possible role of KCNQ channels in regulating the function of pulmonary arteries by determining the ability of the selective KCNQ channel blockers, linopirdine and XE991, to promote pulmonary vasoconstriction. METHODS: The tension developed by rat and mouse intrapulmonary or mesenteric arteries was measured using small vessel myography. Contractile responses to linopirdine and XE991 were measured in intact and endothelium denuded vessels. Experiments were also carried out under conditions that prevent the contractile effects of nerve released noradrenaline or ATP, or block various Ca(2+ )influx pathways, in order to investigate the mechanisms underlying contraction. RESULTS: Linopirdine and XE991 both contracted rat and mouse pulmonary arteries but had little effect on mesenteric arteries. In each case the maximum contraction was almost as large as the response to 50 mM K(+). Linopirdine had an EC(50 )of around 1 μM and XE991 was almost 10-fold more potent. Neither removal of the endothelium nor exposure to phentolamine or α,β-methylene ATP, to block α(1)-adrenoceptors or P2X receptors, respectively, affected the contraction. Contraction was abolished in Ca(2+)-free solution and in the presence of 1 μM nifedipine or 10 μM levcromakalim. CONCLUSION: The KCNQ channel blockers are potent and powerful constrictors of pulmonary arteries. This action may be selective for the pulmonary circulation as mesenteric arteries showed little response. The results imply that the drugs act directly on smooth muscle cells and contraction requires voltage-dependent Ca(2+ )influx. It is concluded that the drugs probably act by blocking KCNQ channels in pulmonary artery myocytes, leading to membrane depolarization and Ca(2+ )influx through L-type Ca(2+ )channels. This implies a functional role for KCNQ channels in regulating the resting membrane potential of pulmonary artery myocytes. BioMed Central 2006 2006-02-20 /pmc/articles/PMC1395307/ /pubmed/16504007 http://dx.doi.org/10.1186/1465-9921-7-31 Text en Copyright © 2006 Joshi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Joshi, Shreena
Balan, Prabhu
Gurney, Alison M
Pulmonary vasoconstrictor action of KCNQ potassium channel blockers
title Pulmonary vasoconstrictor action of KCNQ potassium channel blockers
title_full Pulmonary vasoconstrictor action of KCNQ potassium channel blockers
title_fullStr Pulmonary vasoconstrictor action of KCNQ potassium channel blockers
title_full_unstemmed Pulmonary vasoconstrictor action of KCNQ potassium channel blockers
title_short Pulmonary vasoconstrictor action of KCNQ potassium channel blockers
title_sort pulmonary vasoconstrictor action of kcnq potassium channel blockers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1395307/
https://www.ncbi.nlm.nih.gov/pubmed/16504007
http://dx.doi.org/10.1186/1465-9921-7-31
work_keys_str_mv AT joshishreena pulmonaryvasoconstrictoractionofkcnqpotassiumchannelblockers
AT balanprabhu pulmonaryvasoconstrictoractionofkcnqpotassiumchannelblockers
AT gurneyalisonm pulmonaryvasoconstrictoractionofkcnqpotassiumchannelblockers